NH Consensus Forecast

No. of reports in last year

4

Average Consensus Forecast

560.5

NH Price Target Potential

BrokerageTargetPotential
Geojit Financial Services5613.65%
HDFC Securities5755.99%
ICICIdirect.com5450.82%

NH Ratings

Long term NH rating by FrontPage users


4 NH share price target reports by brokerages below.

See what is analysts view on NH share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.

  1. Home
  2. NH Forum
  3. NH Price Target

NH Share Price Target - Broker Reports - 2021

Geojit Financial Services

8-Jun-21

Geojit Financial Services

8-Jun-21

NH Share Price Target - Broker Reports - 2020

The quarter was soft due to seasonality impact and shutdown of Whitefield facility (Bangalore). New hospitals (SRCC, Gurugram, Dharamshila) continue to see reduction in losses as the ramp-up in these assets. The management is currently focusing on improving efficiency and capacity of existing hospitals and less focus on greenfield or M&A front, which should improve the return ratios gradually. The improvement and sustainability of these vital prints hold key as the focus now shifts to improvement in operating leverage which is visible in 9M performance. The improvement in numbers over the last few quarters is also on the back of judicious case mix identification (more focus on oncology, transplants as well as non-invasive procedures). We continue to believe in the long term prospects of the company on the back of asset-right model and affordability philosophy. We arrive at an SOTP target price of | 430 by valuing the matured hospitals and Cayman Islands at 10x of FY22E EV/EBITDA, new hospitals at 1.5x FY22E EV/sales and other business at 1x FY22E EV/sales.

... Read more

NH Share Price Target - Broker Reports - 2019

A persistent improvement in occupancy rate across all segments coupled with substantial seasonality impact propelled both revenue growth, margins in H1. The new hospitals (SRCC, Gurugram, Dharamshila) continue to see a reduction in losses as the ramp-up in these assets is slowly but surely improving. The management reiterated a significant moderation in capex. On the M&A front, this should improve return ratios gradually. The improvement, sustainability of these vital prints hold key as the focus now shifts to improvement in operating leverage. This was clearly visible in H1 performance. The improvement in numbers over the last few quarters is also on the back of a judicious case mix identification (more focus on transplants as well as non-invasive procedures). We continue to believe in the long term prospects of the company on the back of asset-right model and affordability philosophy. We arrive at an SOTP target price of | 360 by valuing the matured hospitals and Cayman Islands at 8x of FY22E EV/EBITDA, new hospitals at 1.5x FY22E EV/sales and other business at 1x FY22E EV/sales.

... Read more

Recommend Buy with a TP of INR 282
NARH reported strong operating performance in FY19, which is likely to sustain. Given its low-cost model and scale-up in new hospitals, it is well positioned to benefit from growing demand. In the near term, losses from newer hospitals would hurt profitability. At the CMP, the stock trades at an attractive valuation of 12x FY21E EV/EBITDA. We reiterate Buy with a TP of INR 282 on 15x FY21E EV/EBITDA.

... Read more

Overall margins have improved mainly due to strong margins at Cayman and firm margins at the matured hospitals. The new hospitals, SRCC, Gurugram and Dharamshila continue to remain in investment mode for at least next one and a half to three years as the ramp-up in these assets is happening rather slowly. However, the management has reiterated a significant moderation in capex and M&A activities, which should improve the return ratios gradually. That said, the improvement and sustainability of margin holds key as any further slowdown in margins could worsen the situation in the near term. We continue to believe in the long term prospects of the company on the back of the asset-right model and affordability philosophy. We arrive at an SOTP target price of Rs 260 by valuing the matured hospitals and Cayman Islands at 8x of FY21E EV/EBITDA and other hospitals & other businesses at 1x FY21E EV/sales.

... Read more

NH Share Price Target - Broker Reports - 2017

NH Share Price Target - Broker Reports - 2016

Join FrontPage

Hero

FrontPage is Indias favorite stock discussions community

Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.

  • NH Share Price Target Today- Technical Pivot Points (Classic)

    keyboard_arrow_down

    Upside Target 3587.43
    Upside Target 2571.22
    Upside Target 1555.88
    Pivot539.67
    Downside Target 1524.33
    Downside Target 2508.12
    Downside Target 3492.78
  • NH Share Price Target weekly- Technical Pivot Points (Classic)

    keyboard_arrow_down

    Upside Target 3575.27
    Upside Target 2545.18
    Upside Target 1528.47
    Pivot498.38
    Downside Target 1481.67
    Downside Target 2451.58
    Downside Target 3434.87
  • NH Share Price Target monthly- Technical Pivot Points (Classic)

    keyboard_arrow_down

    Upside Target 3584.97
    Upside Target 2558.58
    Upside Target 1524.22
    Pivot497.83
    Downside Target 1463.47
    Downside Target 2437.08
    Downside Target 3402.72
  • NH Share Price Target today- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down

    Upside Target 3571.22
    Upside Target 2559.16
    Upside Target 1551.72
    Pivot539.67
    Downside Target 1527.61
    Downside Target 2520.17
    Downside Target 3508.12
  • NH Share Price Target weekly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down

    Upside Target 3545.18
    Upside Target 2527.31
    Upside Target 1516.26
    Pivot498.38
    Downside Target 1480.51
    Downside Target 2469.46
    Downside Target 3451.58
  • NH Share Price Target monthly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down

    Upside Target 3558.58
    Upside Target 2535.38
    Upside Target 1521.04
    Pivot497.83
    Downside Target 1474.63
    Downside Target 2460.29
    Downside Target 3437.08

SOURCE: Data from DMarket via Quandl. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided as is and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at ones own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

Say hello

Find us at the office

Schwede- Busard street no. 40, 77937 Riyadh, Saudi Arabia

Give us a ring

Smith Waltimyer
+86 488 682 876
Mon - Fri, 10:00-17:00

Join us